Table 1. General characteristics and baseline variables of the included studies.

Study & year	N		Country	Follow-up duration (m)	Age(y)		Sex (M/F)		BMI (Kg/m2)		HbA1c (%)		FPG (mmol/L)		TG (mmol/L)		TC (mmol/L)
	F	P			F	P	F	P	F	P	F	P	F	P	F	P	F	P
Gray DS, 1992	24	24	USA	6	54.8±10.9	56.2±8.4	8/16	14/10	38.2±5.7	39.2±7.1	10.54±2.18	10.21±2.96	8.5±3.1	10.8±4.2	U	U	U	U
O'Kane M, 1994	9	10	UK	12	59.6(51–71)	54.9(23–72)	2/7	4/6	36.8(30.7–53.0)	35.8(30.1–43.2)	9.7(7.3–11.8)	9.2(6.1–11.4)	7.95.9–10.2)	7.2(5.6–10.1)	2.15(1.55–3.75)	1.90(1.29–2.28)	6.1(5.8–6.8)	5.4(4.4–6.0)
Breum L, 1995	20	20	Denmark	12	43.6±9.8	44.3±8.7	13/7	15/5	36.9±4.5	39.5±4.7	7.4±2.2	6.8±1.8	10.1±4.4	8.7±2.3	2.7±2.0	2.7±2.2	6.8±0.9	6.5±2.2
Connolly VM, 1995	11	13	UK	6	67	65	10/1	5/8	32.0(28.7–34.9)	31.5(29.8–33.4)	8.0(7.5–9.8)	8.7(7.4–10.7)	7.3(6.3–12.2)	10.2(6.1–11.7)	U	U	U	U
Daubresse JC, 1996	39	43	Belgium	2	52±1	52±2	U	U	34.5±0.7	34.0±0.8	8.5	8.6	U	U	U	U	U	U

F: Fluoxetine group.

P: Placebo group.

U: Unkown.